Cargando…

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade

SIMPLE SUMMARY: The recent discovery of immune checkpoint inhibitors constituted a breakthrough in cancer treatment, but most patients are resistant to this therapy. Although the co-stimulatory molecule cluster of differentiation (CD) 80 has been detected in several types of tumor cells, its role in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vackova, Julie, Polakova, Ingrid, Johari, Shweta Dilip, Smahel, Michal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072777/ https://www.ncbi.nlm.nih.gov/pubmed/33923750 http://dx.doi.org/10.3390/cancers13081935

Ejemplares similares

Distinct Responsiveness of Tumor-Associated Macrophages to Immunotherapy of Tumors with Different Mechanisms of Major Histocompatibility Complex Class I Downregulation
por: Piatakova, Adrianna, et al.
Publicado: (2021)

Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade
por: Vackova, Julie, et al.
Publicado: (2020)

Experimental Combined Immunotherapy of Tumours with Major Histocompatibility Complex Class I Downregulation
por: Grzelak, Adrianna, et al.
Publicado: (2018)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Poon, Edmund, et al.
Publicado: (2017)

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
por: Šmahel, Michal
Publicado: (2017)

Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
por: Ville, Simon, et al.
Publicado: (2015)

Implementation of Mass Cytometry for Immunoprofiling of Patients with Solid Tumors
por: Poláková, Ingrid, et al.
Publicado: (2019)

CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer
por: Friese, Christina, et al.
Publicado: (2020)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment
por: Broucek, Joseph, et al.
Publicado: (2014)

Systemic Administration of CpG Oligodeoxynucleotide and Levamisole as Adjuvants for Gene-Gun-Delivered Antitumor DNA Vaccines
por: Šmahel, Michal, et al.
Publicado: (2011)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
por: Lesterhuis, W. Joost, et al.
Publicado: (2013)

Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment
por: Fjæstad, Klaire Yixin, et al.
Publicado: (2022)

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
por: Jure-Kunkel, Maria, et al.
Publicado: (2013)

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors
por: Zappasodi, Roberta, et al.
Publicado: (2021)

CD39(+) conventional CD4(+) T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade
por: Bossio, Sabrina N., et al.
Publicado: (2023)

ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity
por: Soldevilla, Mario Martínez, et al.
Publicado: (2019)

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2014)

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
por: Youlin, Kuang, et al.
Publicado: (2012)

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
por: Fan, Xiaozhou, et al.
Publicado: (2014)

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2013)

The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy
por: Wo, Yu Jun, et al.
Publicado: (2019)

CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment
por: Guan, Xiudong, et al.
Publicado: (2021)

Editorial: Tumor microenvironment, inflammation, and resistance to immunotherapies
por: Decock, Julie, et al.
Publicado: (2023)

Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer
por: Lin, Xuan, et al.
Publicado: (2021)

Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity
por: Nawaf, Maher G., et al.
Publicado: (2017)

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1
por: Kleinpeter, Patricia, et al.
Publicado: (2019)

The influence of microenvironment on tumor immunotherapy
por: Zhang, Jieying, et al.
Publicado: (2019)

LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade
por: Hickman, Amber, et al.
Publicado: (2022)

Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors
por: Sun, Lu, et al.
Publicado: (2023)

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
por: Kashyap, Abhishek S., et al.
Publicado: (2020)

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer
por: Wang, Qianqian, et al.
Publicado: (2023)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Role of the tumor immune microenvironment in tumor immunotherapy
por: Zhou, Changsheng, et al.
Publicado: (2022)

Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells
por: Foy, Susan P., et al.
Publicado: (2016)

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy
por: Moertel, Christopher L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_oghk30vtgirh55bknk2vtafmt8